Enrica Sarnicola

Enrica Sarnicola

Auto-generated profile, based on publicly available information

Enrica Sarnicola

Clinica degli Occhi Sarnicola, Grosseto, Italy

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2012 in Cornea
Verified
Journal Article
Closed access
VSVincenzo Sarnicola
Vincenzo Sarnicola
PTPatricia Toro
Patricia Toro
CSCaterina Sarnicola
Caterina Sarnicola
ESEnrica Sarnicola
Enrica Sarnicola
ARAndrew RUGGIERO
Andrew RUGGIERO
Purpose: To determine corneal graft survival rates up to 10 years in a large consecutive series of deep anterior lamellar keratoplasties (DALKs). Methods: A retrospective, consecutive, noncomparative cases series of DALK procedures in a total of 806 eyes of 711 patients with stromal diseases and healthy endothelium performed between 2000 and 2009. Inclusion criterion was surgery performed by a single surgeon (660 eyes), with at least 6 months of follow-up. Graft survival was analyzed using the Kaplan–Meier method. Endothelial loss was analyzed with the Gaussian distribution and the χ2 methods. Follow-up time, and preoperative and postoperative endothelial cell density (ECD) were considered in the analyses. Results: Six hundred sixty eyes of 502 patients met the entry criteria. Mean length of follow-up was 4.5 years (range, 0.5–10 years). We report an average graft survival rate of 99.3% (range, 98.5%–100%); 3 eyes (0.45%) experienced graft failure and 1 eye (0.15%) developed late endothelial failure because of an intraoperative complication. Predominant indications for DALK in this series were keratoconus (74%), postherpetic keratitis scarring (15%), and corneal stromal opacities of different etiology (11%). Endothelial loss from preoperative levels averaged 11% (range, 10%–13%) at 6 months through 10 years after DALK. ECD was unchanged between 6 months postoperatively and the last follow-up visits. Conclusions: DALK is a successful form of transplantation in stromal corneal disorders with healthy endothelium, with higher long-term graft survival rates and stable ECD 6 months postoperatively. DALK survival rates do not vary significantly over time.

1 January 2016 in Cornea
Verified
Journal Article
Closed access
ESEnrica Sarnicola
Enrica Sarnicola
CSCaterina Sarnicola
Caterina Sarnicola
FSFrancesco Sabatino
Francesco Sabatino
GTGian Marco Tosi
Gian Marco Tosi
PPPaolo Perri
Paolo Perri
VSVincenzo Sarnicola
Vincenzo Sarnicola
To evaluate the success (eradication of infection) or failure (recurrence of infection in the cornea or sclera, or endophthalmitis) of early therapeutic deep anterior lamellar keratoplasty (DALK) for active Acanthamoeba keratitis (AK) poorly responsive to medical treatment. Retrospective, noncomparative case series of 11 patients (11 eyes) affected by active AK poorly responsive to medical treatment who underwent early therapeutic DALK. Surgery was performed in all cases within 30 to 60 days from the onset of symptoms. Corneal ulcer depth was less than 300 μm in all cases. A 3-drug combination (chlorhexidine gluconate, propamidine isethionate, and neomycin sulfate) was the antiamoebic protocol used preoperatively and postoperatively. Cannula big bubble and "layer-by-layer" manual dissection techniques were performed. Eradication of infection, episodes of rejection, postoperative endothelial cell density, and the best spectacle-corrected visual acuity were evaluated. Histologic examination of surgical margins was performed, and margin clearance was assessed. Mean follow-up was approximately 2 years. Four descemetic DALK and 7 predescemetic DALK were performed. One small Descemet membrane rupture occurred. Peripheral surgical margins were free of infection in all cases. Deep surgical margins not free from infection were found in 2 cases. However, no episode of infection recurrence was observed. The postoperative average best spectacle-corrected visual acuity was 0.8 (range, 0.6-1.0). No case of rejection was recorded. Early therapeutic DALK could be considered a new approach to eradicate active infection in AK cases poorly responsive to medical treatment, with significant ulcer in the optical zone. Further studies are needed to validate this new indication for DALK.

6 April 2020 in Cornea
Verified
Journal Article
Closed access
ACAlbert Y. Cheung
Albert Y. Cheung
MEMedi Eslani
Medi Eslani
KKKhaliq H. Kurji
Khaliq H. Kurji
EWElizabeth Lpn Wright
Elizabeth Lpn Wright
ESEnrica Sarnicola
Enrica Sarnicola
EHEdward J. Holland
Edward J. Holland
Purpose: To compare the long-term outcomes of living-related conjunctival limbal allograft (lr-CLAL) with keratolimbal allograft (KLAL) in patients with limbal stem cell deficiency. Methods: A retrospective, comparative, interventional cohort of patients with bilateral total limbal stem cell deficiency who underwent surgical treatment with a KLAL or lr-CLAL procedure alone (not combined with any other ocular surface stem cell transplantation procedures) with a minimum follow-up of 1 year and who received systemic immunosuppression. Ocular surface stability, best-corrected visual acuity (BCVA), and postoperative complications at the last follow-up were the main outcome measures. Results: There were 224 eyes that underwent KLAL alone and 63 eyes that underwent lr-CLAL alone, with a mean follow-up time for all eyes of 7.2 years (range 1.0–16.0 years). For lr-CLAL eyes, 82.5% maintained a stable ocular surface compared with 64.7% of KLAL eyes at the last follow-up. Only 6.3% of lr-CLAL eyes demonstrated a failed ocular surface compared with 15.6% of KLAL eyes. The mean BCVA was 20/158 for KLAL eyes compared with 20/100 for lr-CLAL eyes at the last follow-up. A smaller proportion of lr-CLAL eyes (30.2% compared with 43.3%) developed an episode of acute rejection, and a higher proportion of these episodes resolved with treatment in the lr-CLAL group (79.0% compared with 53.6%). Conclusions: lr-CLAL demonstrates lower rejection rates, improved graft survival, and better BCVA compared with KLAL. Both careful preoperative donor selection and triple-agent systemic immunosuppression (including tapered systemic corticosteroids) are critical to optimizing the ocular surface stem cell transplantation outcomes.

1 December 2017 in Eye
Verified
Journal Article
Closed access
FSFrancesco Sabatino
Francesco Sabatino
ESE Sarnicola
E Sarnicola
CSC Sarnicola
C Sarnicola
GTG M Tosi
G M Tosi
PPP Perri
P Perri
VSV Sarnicola
V Sarnicola

21 June 2017 in Cornea
Verified
Journal Article
Closed access
PDF file
ACAlbert Y. Cheung
Albert Y. Cheung
ESEnrica Sarnicola
Enrica Sarnicola
EHEdward J. Holland
Edward J. Holland
Purpose: To investigate the incidence of limbal stem cell deficiency (LSCD) in donor eyes after conjunctival limbal autograft (CLAU). Methods: An observational retrospective review was performed on all patients who underwent CLAU alone, combined keratolimbal allograft with CLAU (“Modified Cincinnati Procedure”), or combined living-related conjunctival limbal allograft (lr-CLAL) with CLAU having ≥6 months of follow-up after surgery. The outcome measures were best-corrected visual acuity (BCVA) and ocular surface status. Results: The inclusion criteria were fulfilled by 45 patients. Of these, 26 patients underwent CLAU, 18 underwent combined keratolimbal allograft/CLAU, and 1 underwent combined lr-CLAL/CLAU. Mean age at the time of surgery was 39.6 years. Mean logMAR preoperative BCVA was −0.08. There were no operative complications. The mean follow-up duration after surgery was 48.3 months (range 8.3–181.5 mo). At last follow-up, all eyes maintained a stable ocular surface, and mean logMAR BCVA was −0.05. Conclusions: With the advent of newer ocular surface transplantation methods, there has been concern that CLAU carries the theoretical risk of inducing LSCD. Our long-term clinical results following donor eyes after CLAU demonstrate no signs of LSCD.

23 January 2019 in Cornea
Verified
Journal Article
Closed access
ESEnrica Sarnicola
Enrica Sarnicola
CSCaterina Sarnicola
Caterina Sarnicola
ACAlbert Y. Cheung
Albert Y. Cheung
EHEdward J. Holland
Edward J. Holland
VSVincenzo Sarnicola
Vincenzo Sarnicola
Deep anterior lamellar keratoplasty (DALK) is the ideal surgery for corneal stromal diseases with a healthy endothelium. This technique offers substantial advantages compared with penetrating keratoplasty, primarily the avoidance of endothelial rejection and longer graft survival. Several DALK techniques have been described and classified into 2 categories, descemetic DALK (dDALK) and predescemetic DALK (pdDALK) depending on whether Descemet membrane-endothelium was thought to be exposed or minimal residual stroma was left behind. This classification was crucial to identify the conditions to achieve good visual outcomes with pdDALK techniques. The recent description of Dua's layer, also known as the pre-Descemet layer, has demonstrated that a very thin layer of stroma exists in some instances where Descemet membrane was thought to be completely exposed. This concept has generated a discrepancy between the previous and current applications of the terms “dDALK” and “pdDALK.” We offer a summary of the published literature and a proposal for a new and more appropriate DALK nomenclature. We suggest adding the terms subtotal anterior lamellar keratoplasty (STALK) and total anterior lamellar keratoplasty (TALK).